Ofimedicine

Ophi Medicine is a clinical-stage biopharmaceutical company based in Shanghai, China, dedicated to discovering and developing innovative small molecule drugs for autoimmune and inflammatory diseases. The company leverages its proprietary structure-based drug design (SBDD) platform to develop highly selective inhibitors, particularly focusing on the Janus kinase (JAK) family. Its lead candidate, OFI-001, is a potent and selective TYK2 inhibitor currently in Phase 2 clinical trials for indications such as psoriasis and ulcerative colitis. Ophi Medicine aims to provide safer and more effective oral treatment options for patients with chronic conditions that are currently underserved by existing therapies. The company is supported by leading venture capital firms, including Lilly Asia Ventures and Qiming Venture Partners.